Sarepta Therapeutics Halted Ahead of FDA Decision
Market News

Sarepta Therapeutics Halted Ahead of FDA Decision

The trading of Sarepta Therapeutics (NASDAQ:SRPT) shares has hit the pause button, as an independent expert group from the FDA is convening on Friday to discuss the company’s application to market its Duchenne muscular dystrophy targeted gene therapy, SRP-9001. The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee members will cast a vote by the end of the meeting to decide on the therapy’s approval.

Given the high stakes, several investment firms have been trying their hand at predicting the meeting’s outcome. Analyst Neena Bitritto-Garg, noting the brief two-hour discussion window before voting, anticipates a one-sided decision. Meanwhile, SVB Securities analyst Joseph Schwartz warns that the FDA’s briefing documents create an uncertain atmosphere for the panel members, and Evercore ISI analysts are betting on a 50%-60% approval chance.

Overall, Wall Street analysts have a consensus price target of $170.94 on SRPT stock, implying over 42% upside potential, as indicated by the graphic above.

Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
RUT
Russell 2000
TNX
10-Yr-Bond
Bitcoin

Popular Articles